Sai Life Sciences Ltd
Incorporated in 1999, Sai Life Sciences
Ltd carries out contract research and manufacturing activities for customers
engaged in pharmaceutical and bio
technology industries[1]
- Market Cap ₹ 15,958 Cr.
- Current Price ₹ 764
- High / Low ₹ 809 / 635
- Stock P/E 92.0
- Book Value ₹ 104
- Dividend Yield 0.00 %
- ROCE 13.9 %
- ROE 10.9 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company's working capital requirements have reduced from 146 days to 109 days
Cons
- Stock is trading at 7.35 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 8.50% over last 3 years.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap BSE IPO
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 695 | 725 | 751 | 841 | 1,157 | 1,419 | 1,642 | |
| 520 | 556 | 587 | 716 | 990 | 1,131 | 1,252 | |
| Operating Profit | 175 | 170 | 164 | 125 | 167 | 288 | 390 |
| OPM % | 25% | 23% | 22% | 15% | 14% | 20% | 24% |
| 6 | 18 | 27 | 28 | 27 | 29 | 37 | |
| Interest | 24 | 21 | 32 | 51 | 74 | 81 | 70 |
| Depreciation | 44 | 52 | 72 | 80 | 88 | 107 | 126 |
| Profit before tax | 112 | 114 | 88 | 22 | 33 | 129 | 232 |
| Tax % | 35% | 30% | 25% | 30% | 26% | 26% | 25% |
| 73 | 80 | 65 | 16 | 24 | 95 | 173 | |
| EPS in Rs | 8.32 | ||||||
| Dividend Payout % | 0% | 0% | 0% | 444% | 279% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | 25% |
| TTM: | 16% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | 241% |
| TTM: | 82% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 9% |
| Last Year: | 11% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 18 | 18 | 18 | 18 | 21 |
| Reserves | 700 | 778 | 850 | 873 | 895 | 993 | 2,147 |
| 250 | 304 | 637 | 752 | 870 | 868 | 287 | |
| 246 | 291 | 312 | 464 | 349 | 361 | 682 | |
| Total Liabilities | 1,212 | 1,389 | 1,816 | 2,106 | 2,131 | 2,240 | 3,137 |
| 373 | 617 | 659 | 701 | 923 | 1,074 | 1,378 | |
| CWIP | 116 | 79 | 236 | 345 | 151 | 107 | 124 |
| Investments | 0 | 22 | 63 | 64 | 80 | 80 | 114 |
| 722 | 671 | 858 | 996 | 977 | 979 | 1,521 | |
| Total Assets | 1,212 | 1,389 | 1,816 | 2,106 | 2,131 | 2,240 | 3,137 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 127 | 109 | -26 | 88 | 221 | 251 | 330 | |
| -158 | -259 | -279 | -95 | -111 | -190 | -565 | |
| 268 | -1 | 304 | 81 | -190 | -85 | 314 | |
| Net Cash Flow | 237 | -152 | -2 | 75 | -80 | -24 | 80 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 123 | 136 | 98 | 103 | 87 | 67 | 78 |
| Inventory Days | 86 | 77 | 124 | 185 | 123 | 73 | 96 |
| Days Payable | 208 | 247 | 244 | 284 | 176 | 161 | 270 |
| Cash Conversion Cycle | 0 | -34 | -21 | 4 | 35 | -22 | -96 |
| Working Capital Days | 133 | 144 | 250 | 246 | 190 | 140 | 109 |
| ROCE % | 13% | 9% | 4% | 6% | 11% | 14% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
2d - Allotment of equity shares under Management ESOP Plan 2018 ("MESOP 2018").
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
2d - Revision in intimation under regulation 30 of LODR dated 23rd May 2025 and 09 June 2025 with respect to the allotment of equity shares under …
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
2d - Revision in intimation under Regulation 30 of LODR dated 23rd May 2025 and 09th June 2025 with respect to the allotment of Equity Shares on …
-
Closure of Trading Window
25 Jun - Trading window closed from 1 July 2025 till 48 hours post Q1 results announcement.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 23 Jun
Concalls
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Feb 2025TranscriptNotesPPT REC
Business Overview:[1]
a) SLS is a Hyderabad-based contract research development and manufacturing organisation in the pharmaceutical sector with a significant presence in regulatory markets of US and Europe.
b) It offers integrated services across the pharmaceutical lifecycle from discovery services to development and manufacturing of new chemical entities to global innovator pharmaceutical and biotechnology companies.
c) In FY24, company has completed
200+ discovery programmes and 40+ programmes have advanced to clinical
phases.
d) SLS has a fully integrated in-house
synthetic and medicinal chemistry, drug metabolism, biology, pharmacokinetics
and toxicology.
e) In terms of therapy, they have worked in oncology and other key therapy areas include central nervous system, inflammation and anti
virals.
f) SLS provides its services to 17 out of the top 20 global pharmaceutical companies and several biotechnology companies.